Itraconazole for chronic pulmonary aspergillosis: Longer is better

A randomized controlled trial in India demonstrated that 12 months of oral itraconazole was superior to a 6-month regimen in reducing relapses of chronic pulmonary aspergillosis, researchers reported in The Lancet Infectious Diseases.
“We had observed chronic pulmonary aspergillosis relapses in about 50% of patients treated with 6 months of oral itraconazole after treatment discontinuation. Also, many patients required prolonged therapy with oral itraconazole,” Inderpaul S. Sehgal, MD, DM, an assistant professor in the department of pulmonary medicine at the Postgraduate Institute

A randomized controlled trial in India demonstrated that 12 months of oral itraconazole was superior to a 6-month regimen in reducing relapses of chronic pulmonary aspergillosis, researchers reported in The Lancet Infectious Diseases.
“We had observed chronic pulmonary aspergillosis relapses in about 50% of patients treated with 6 months of oral itraconazole after treatment discontinuation. Also, many patients required prolonged therapy with oral itraconazole,” Inderpaul S. Sehgal, MD, DM, an assistant professor in the department of pulmonary medicine at the Postgraduate Institute